Status:
UNKNOWN
Residual Renal Function Preservation in Peritoneal Dialysis Patients
Lead Sponsor:
Second Xiangya Hospital of Central South University
Collaborating Sponsors:
Baxter Healthcare Corporation
Conditions:
Chronic Renal Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Aldosterone blockade is useful in preserving residual renal function in patients on PD.The long term efficacy of dual blockade of the RAAS is better than monotherapy.
Detailed Description
Residual renal function has been proven to contribute to improved survival and quality of life of dialysis patients. It is now recognized as an important factor in the prognosis of PD.The RAAS system ...
Eligibility Criteria
Inclusion
- Patients who having been on PD continuously for one month, urine volume\>600 ml/d, residual renal function\>2ml/min/1.73m2, blood pressure\>120/70mmHg, serum potassium levels\<5.5mmol/l, stable clinical condition.
Exclusion
- Patients with infectious systemic disease, peritonitis during the preceding 1 month, who had taken ACEI/ARBs in the 3 preceding months, spirolactone in the 2 preceding weeks, intolerance to ACEI/ARBs, CHF, MI, malignant hypertension and stroke within the preceding 6 months.
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT02190318
Start Date
November 1 2013
End Date
December 1 2015
Last Update
August 1 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changsha, Hunan, China, 410000